FRAZER, Pa., March 21 /PRNewswire-FirstCall/ -- On March 23, 2006 the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research will hold a meeting of the Psychopharmacologic Drugs Advisory Committee. The meeting will focus on a New Drug Application for modafinil for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
Cephalon has scheduled an investor conference call on Thursday, March 23, 2006 at 6:00 p.m. U.S. EST to discuss with investors the proceedings at the FDA advisory committee.
March 23, 2006 Schedule 5:50 p.m. EST To participate in the conference call, dial 1-913-981-4901 and refer to Conference Code Number 8645966 6:00 p.m. EST Conference call begins promptly. Simultaneous Webcast
The public may access a live webcast of the conference call from the Events page of the Investor Information section of the company’s website, http://www.cephalon.com. Please click on the link and follow the prompts for registration and access.
If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EST, March 30, 2006. To listen to the audio replay, dial 1-719-457-0820 and use the Conference Code Number 8645966.
Additional information presented on the conference call may be made available on the Investor page of the company’s website.
Cephalon, Inc.
CONTACT: Robert S. (Chip) Merritt, Cephalon, +1-610-738-6376,cmerritt@cephalon.com
Web site: http://www.cephalon.com//
Company News On-Call: http://www.prnewswire.com/comp/134563.html/
